Benitec Biopharma Inc.
NCM: BNTCLive Quote
📈 ZcoreAI Score
Our AI model analyzes Benitec Biopharma Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get BNTC Z-Score →About Benitec Biopharma Inc.
Healthcare
Biotechnology
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
📊 Fundamental Analysis
Benitec Biopharma Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -33.5%, which indicates that capital utilization is currently under pressure.
At a current price of $11.42, BNTC currently sits at the 22nd percentile of its 52-week range (Range: $9.85 - $17.15).
🏥 Financial Health
🔴
Profit Margin
Weak
⚠️
Debt/Equity
Moderate
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$391.19M
Trailing P/E
--
Forward P/E
-1.21
Beta (5Y)
0.12
52W High
$17.15
52W Low
$9.85
Avg Volume
157K
Day High
Day Low